Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime-Boost Dengue Vaccination Schedules
NCT03141138Phase 1Unknown
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TDENV-PIV and T-DEN vaccine in dengue fever (2 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Number of Subjects With At Least One Local Solicited Adverse Event. Status: unknown.
02
Drugs
TDENV-PIVT-DEN vaccine
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03141138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141138.